|
|
|
|
|
|
|
30.04.26 - 17:36
|
Merck & Co Aktie: Operatives Geschäft stärker als erwartet (Aktiencheck)
|
|
|
Wien (www.aktiencheck.de) - Merck & Co-Aktienanalyse der Raiffeisen Bank International AG:
Julian Lindinger, Analyst der Raiffeisen Bank International AG (RBI), nimmt in einer aktuellen Aktienanalyse die Aktie von Merck & Co Inc. (ISIN: US58933Y1055, WKN: A0YD8Q, Ticker-Symbol: 6MK, NYSE-Symbol: MRK) unter die Lupe. [mehr]...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30.04.26 - 12:36
|
Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones (Business Wire)
|
|
|
Sales Growth Driven by Continued Strength in Oncology and Animal Health, Plus Increasing Contributions From Launches
Total Worldwide Sales Were $16.3 Billion (5% Growth; 3% Growth ex-FX)
KEYTRUDA/KEYTRUDA QLEX1 Sales Were $8.0 Billion (12% Growth; 8% Growth ex-FX); Includes KEYTRUDA QLEX Sales of $128 Million
WINREVAIR Sales Were $525 Million (88% Growth; 87% Growth ex-FX)
Animal Health Sales Were $1.8 Billion (13% Growth; 6% Growth ex-FX)
GAAP Loss per Share Was $1.72; Non-GAAP Loss per Share Was $1.28; GAAP and Non-GAAP Loss per Share Include a Charge of $3.62 per Share for the Acquisition of Cidara
Presented New Data From Cardio-Pulmonary Pipeline at ACC.26, Including Positive Results From Phase 3 CORALreef AddOn Trial
Received U.S. FDA Approval for IDVYNSO, a Once-Daily, Oral Treatment for Certain Adults With Virologically Suppressed HIV-1
Achieved Multiple Significant Regulatory and Clinical Milestones Across Oncology Pipeline
Announced Agreement To Acquire Terns Pharmaceuticals, Inc. and Expand Hema...
|
|
|
|
|
|
|
|
|
27.04.26 - 11:48
|
Sun Pharma to acquire Organon for $11.75bn (PBR)
|
|
|
Organon, created through a spinoff from Merck & Co (MSD) in 2021, distributes more than 70 products across women's health and general medicines, including biosimilars, reaching 140 countries.
The post Sun Pharma to acquire Organon for $11.75bn appeared first on Pharmaceutical Business review....
|
|
|
|
|
24.04.26 - 12:51
|
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc. (Business Wire)
|
|
|
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Merck's pending acquisition of Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN) expired at 11:59 p.m., Eastern Time, on April 23, 2026.
As previously announced on April 7, 2026, Merck commenced, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Terns, for $53.00 net in cash for each share of Terns common stock validly tendered and not validly withdrawn in the offer, without interest and less any applicable tax withholding. The expiration of the HSR waiting period satisfies one of the conditions necessary for the consummation of the tender offer. Consummation of the tender offer remains subject to other conditions described in the tender offer statement on Schedule TO filed with the U.S. Securities and Exc...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
